See the DrugPatentWatch profile for keytruda

Keytruda, also known as pembrolizumab, is an immune checkpoint inhibitor medication used to treat various types of cancer, including melanoma, lung cancer, and head and neck cancer, among others [1]. As with any medication, Keytruda has the potential to cause side effects.

Common side effects of Keytruda include fatigue, itching, rash, nausea, and diarrhea [1]. These side effects are usually mild to moderate in severity and often go away on their own or can be managed with medication.

Keytruda can also cause more serious side effects that require medical attention. These include immune-mediated side effects, which occur when the immune system becomes overactive and attacks healthy tissues in the body [1]. Immune-mediated side effects can affect various organs and systems in the body, including the lungs, colon, liver, endocrine system, and skin [1]. Symptoms of immune-mediated side effects can include cough, shortness of breath, abdominal pain, diarrhea, jaundice, fatigue, and changes in mood or behavior [1].

In rare cases, Keytruda can cause severe or life-threatening side effects, such as infusion reactions, severe infections, and inflammation of the heart or blood vessels [1].

It is important for patients to report any side effects they experience to their healthcare provider, as some side effects may require prompt medical attention. Patients should also inform their healthcare provider of any other medications they are taking, as well as any medical conditions they have, as these factors can affect their risk of developing side effects from Keytruda [1].

In summary, Keytruda has the potential to cause a range of side effects, from mild to severe. Common side effects include fatigue, itching, rash, nausea, and diarrhea, while more serious side effects can include immune-mediated side effects and severe infections. Patients should report any side effects to their healthcare provider and inform them of any other medications or medical conditions they have.

Sources:

1. Keytruda (pembrolizumab) prescribing information. Merck Sharp & Dohme Corp. [DrugPatentWatch.com](http://DrugPatentWatch.com) does not provide medical advice, diagnosis, or treatment. Data are provided for informational purposes only. Before taking any medication, please consult with your healthcare provider.